Regencell Bioscience (NASDAQ:RGC) Trading 11.1% Higher - Time to Buy?

Key Points

• Regencell shares jumped about 11.1% to roughly $30.66 on Thursday (intraday high $30.96), though volume was ~189,889 shares, down ~43% from the average.
• Multiple law firms have filed or are soliciting participation in a class action alleging securities fraud and possible misrepresentation (including questions about the company’s R&D spend versus its valuation), with lead‑plaintiff deadlines in mid‑June.
• Analysts maintain a Sell view (Weiss Ratings reaffirmed "sell (e+)") and institutional ownership remains minimal at about 0.13%, despite a few recent small stakes being added.

Regencell Bioscience Holdings Limited (NASDAQ:RGC - Get Free Report) rose 11.1% during trading on Thursday . The company traded as high as $30.96 and last traded at $30.6610. Approximately 189,889 shares traded hands during trading, a decline of 43% from the average daily volume of 332,522 shares. The stock had previously closed at $27.59.

Key Stories Impacting Regencell Bioscience

Here are the key news stories impacting Regencell Bioscience this week:

• Negative Sentiment: Pomerantz LLP announced a formal class action filed in the U.S. District Court for the District of Maryland against Regencell and certain officers covering the Oct. 28, 2024–Oct. 31, 2025 period, seeking damages under Sections 10(b) and 20(a). Pomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limited and Certain Officers - RGC
• Negative Sentiment: Rosen Law Firm and related Rosen notices remind investors of a lead‑plaintiff deadline in mid‑June and solicit potential clients for the same securities‑fraud matter. Multiple Rosen releases increase publicity around the litigation. ROSEN Encourages Regencell Bioscience Holdings Limited Investors to Secure Counsel ... - RGC
• Negative Sentiment: Levi & Korsinsky highlights allegations that Regencell may have misrepresented business fundamentals (citing a ~$1M R&D budget vs. a multibillion valuation) and reminds investors of the June lead‑plaintiff deadline—an allegation that, if pursued, could be materially damaging. Levi & Korsinsky Reminds Regencell Bioscience Holdings Investors ... - RGC
• Negative Sentiment: Glancy Prongay Wolke & Rotter, Bragar Eagel & Squire, Bronstein Gewirtz & Grossman, Faruqi & Faruqi, Robbins LLP and others have issued alerts or solicitations about the same class action and lead‑plaintiff timeline, amplifying investor awareness and potential participation in the suit. Examples: Glancy/BusinessWire, Bragar/GlobeNewswire, Bronstein/GlobeNewswire, Faruqi/PR Newswire, Robbins/PR Newswire. Glancy Prongay Wolke & Rotter LLP Encourages Regencell Shareholders To Inquire ...
• Negative Sentiment: Kaplan Fox and other firms also posted investor alerts urging contact before the lead‑plaintiff deadline, adding to the volume of solicitations and press coverage around the litigation. RGC CLASS ACTION DEADLINE: Kaplan Fox Encourages Investors ...

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Regencell Bioscience in a research note on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Regencell Bioscience has an average rating of "Sell".

Regencell Bioscience Trading Up 14.1%

The stock's 50 day moving average price is $27.07 and its 200 day moving average price is $23.76.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of RGC. Seven Fleet Capital Management LP acquired a new stake in Regencell Bioscience during the 4th quarter worth approximately $92,000. Vident Advisory LLC increased its position in Regencell Bioscience by 65.7% during the 4th quarter. Vident Advisory LLC now owns 29,934 shares of the company's stock worth $629,000 after purchasing an additional 11,866 shares in the last quarter. Hudson Bay Capital Management LP acquired a new stake in Regencell Bioscience during the 4th quarter worth approximately $275,000. XTX Topco Ltd acquired a new stake in Regencell Bioscience during the 3rd quarter worth approximately $598,000. Finally, BNP Paribas Financial Markets acquired a new stake in Regencell Bioscience during the 2nd quarter worth approximately $768,000. Institutional investors and hedge funds own 0.13% of the company's stock.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.